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SIGNIFICANCE STATEMENT 
 
Antibody-mediated rejection (AMR) is associated with a poor transplant outcome. 
Pathogenic alloantibodies are usually directed against human leucocyte antigens (HLAs). 
However, the evidence of AMR in the absence of anti-HLA antibodies suggests the presence 
of non-anti-HLA antibodies, which are designated anti-endothelial cell antibodies (AECAs). 
This manuscript describes the clinicopathological profiles of kidney recipients who 
experienced acute rejection with microvascular inflammation within the first 3 months after 
transplantation in the absence of anti-HLA donor-specific antibodies. A new endothelial 
crossmatch, combined with transcriptomic and proteomic analyses, revealed that prior to 
transplantation, these patients carried unknown AECAs in their sera that specifically 
targeted the glomerular microvascular endothelium. An assessment of these unknown 
AECAs with potential deleterious effects may provide important diagnostic tools to prevent 
AMR. 
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ABSTRACT 
Background: Although the majority of antibody-mediated rejections (AMRs) of renal 
allografts are due to anti-HLA antibodies, non-anti-HLA antibodies have also been postulated 
to contribute. The occurrence of non-anti-HLA-associated AMRs remains associated with 
unresolved diagnostic and therapeutic issues. 
Methods: Through a nationwide study, we identified kidney transplant recipients (KTRs) 
without anti-HLA donor-specific antibodies who experienced acute graft dysfunction within 
the first 3 months after transplantation and showed severe microvascular injury in a biopsy 
(called acute microvascular rejection, AMVR) to better understand the pathological 
mechanisms of these rejections. 
Results: A highly selected cohort of 38 patients with AMVR was identified. AMVR occurred at 
22.0±26.2 days post-transplantation. Biopsies revealed intense microvascular inflammation 
with a mean Banff glomerulitis and peritubular capillaritis (g+ptc) score of 3.9±0.25, 
vasculitis in 60.5% of cases, interstitial hemorrhages in 31.6% of cases and thrombotic 
microangiopathy in 15.8% of cases. Compared to a control group of stable KTRs, patients 
with AMVR did not show a significant increase in angiotensin type 1 receptor (AT1R), 
endothelin-1 type A (ETAR) or natural polyreactive antibodies (NAbs). Using the threshold of 
10 IU/mL, 26% of the tested AMVR were found positive for AT1R Abs. A homemade 
endothelial crossmatch identified a common IgG response that was specifically directed 
against constitutively expressed antigens of microvascular glomerular cells in patients with 
AMVR. Using a combination of transcriptomic and proteomic approaches, we identified new 
targets of non-HLA antibodies with little redundancy among individuals. 
Conclusions: Based on our results, preformed IgG antibodies targeting non-HLA antigens 
expressed on glomerular endothelial cells are associated with early AMVR and in vitro cell-
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based assays are needed to improve risk assessments before transplantation.
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INTRODUCTION 
 
Despite the development of potent immunosuppressive regimens, antibody-mediated 
rejection (AMR) remains a significant hurdle to long-term organ acceptance. Although 
histological findings suggestive of AMR (i.e., microvascular inflammation) usually indicate an 
anti-human leukocyte antigen (HLA)-mediated injury, a subset of patients develop these 
lesions in the absence of detectable anti-HLA donor-specific antibodies (DSAs). The potential 
involvement of non-HLA antibodies (Abs) is mentioned in the current Banff classification, 
which requires the presence of “serological evidence of DSAs against HLA or other antigens”. 
However, in the absence of other, clearly defined antigens, the assumption that acute 
rejections with significant microvascular inflammation (called AMVRs hereafter, for acute 
microvascular rejections) are true AMRs remains hypothetical. In addition, although this 
issue is of utmost importance for treatment decisions, a clear indication that the observed 
graft injury is induced by Abs may be difficult to obtain.  
These particular types of immune injuries are presumed to be due to Abs that react with 
non-HLA antigens expressed on endothelial cells (ECs). These Abs might be alloantibodies 
directed against non-HLA polymorphic antigens that differ between the recipient and donor 
or autoantibodies that recognize self-antigens following a disruption of self-tolerance1. The 
identification and characterization of pathogenic anti-endothelial cell Abs (AECAs) would 
improve our understanding of the mechanisms involved in AMRs and would enable the 
development of new tools for patient monitoring. Several hurdles hamper the identification 
of these AECAs. First, the development of acute renal dysfunction with histological lesions 
suggestive of AMR in the absence of anti-HLA DSAs is a relatively rare event. Consequently, 
previous studies that aimed to identify AECAs often included patients with heterogeneous 
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clinical presentations ranging from hyperacute rejection2-4 to chronic allograft dysfunction4, 5 
or patients with a positive EC crossmatch independent of any clinical presentation6. Second, 
the identification of deleterious non-HLA Abs is particularly difficult to achieve in long-term 
patients, as a broad autoantibody response develops over time after transplantation7, 8. 
We aimed to study a highly selected cohort of patients with a homogeneous clinical and 
pathological presentation of AMVR without anti-HLA DSAs during the first 3 months post-
transplantation to overcome these challenges. We reasoned that early AMVR would likely be 
caused by preformed AECAs, facilitating their identification in pretransplant serum samples. 
We report here the clinicopathological description of this cohort and our efforts to identify 
the pathogenic AECAs. 
 
METHODS 
 
Patients 
Kidney transplant recipients (KTRs) were identified through a nationwide survey aimed at 
identifying suspected cases of early AMVRs of renal allografts in the absence of anti-HLA 
DSAs. Inclusion criteria were a first transplantation or retransplantation, a deceased or living 
donor, acute dysfunction or delayed graft function occurring within the first 3 months post-
transplantation, histological features of microvascular inflammation with a glomerulitis and 
peritubular capillaritis (g+ptc) score greater than or equal to 3 according to the Banff 
classification, and the absence of historical or current anti-HLA DSA (A/B/Cw/DR/DQ/DP), as 
assessed using a Luminex® single-antigen bead assay (all mean fluorescence intensities 
(MFIs)<500). All biopsies were centrally reassessed, and the absence of anti-HLA DSAs was 
also centrally confirmed (see the Supplementary Methods for details). 
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For the case-control histological study (Figure 1), a control group of 20 KTRs with early 
full-blown AMR who presented with anti-HLA DSAs in the first three months was identified. 
The patients were matched for age, gender, time of transplantation and immunosuppressive 
regimen at transplantation.  
For the case-control biological study (Figure 1), a second control group of 10 highly stable 
patients (i.e., no rejection during the first year) was identified. Patients in this control group 
were also matched to patients in the AMVR group for age, gender, time of transplantation 
and immunosuppressive regimen at transplantation. 
 
Non-HLA antibody detection 
Methods for the detection of non-HLA Abs, including anti-MICA, anti-AT1R, anti-ETAR, 
natural Abs and Abs against a panel of 62 non-HLA antigens, in patients’ sera are described 
in detail in the Supplementary Methods. 
 
EC crossmatch  
Different types of ECs were incubated with patients’ serum samples, and IgG fixation was 
detected using flow cytometry. A comparative analysis of the reactivity of the patient’s 
serum was performed on parallel crossmatches using primary cultures of non-donor-specific 
arterial ECs and the immortalized human glomerular microvascular EC line CiGEnC (see the 
Supplementary Methods for details).  
 
RNA sequencing (RNAseq) and protein array 
RNAseq was performed to assess the differences in the transcriptomes between 
microvascular and macrovascular ECs. Patients’ serum samples were applied to a protein 
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array to assess the seroreactivity of stable KTRs and patients with AMVR (see the 
Supplementary Methods for details). 
 
Statistics 
The results are presented as the means±SD for continuous variables, unless specified 
otherwise. Frequencies of categorical variables are presented as numbers and percentages. 
Analyses were performed with GraphPad Prism software (version 5.00; GraphPad Software, 
San Diego, CA). For statistical comparisons of the clinical data between two groups, we used 
unpaired two–tailed t tests and a chi-square test. For statistical comparisons of the in vitro 
data, we used nonparametric tests. P values<0.05 were considered significant. 
A detailed description of the statistical methods used to analyze the protein array and 
RNAseq data is provided in the Supplementary Methods. 
 
RESULTS 
 
Clinicopathological description 
A nationwide survey identified 51 KTRs (from 21 centers) with suspected early AMVR in 
the absence of anti-HLA DSAs (DSA- AMVR). After a central reassessment of anti-HLA DSAs 
(AC) and a central histological analysis (MR and JPD), the final cohort included 38 patients 
with confirmed early acute DSA- AMVR (Figure 1). 
Patients were 43.0±14.3 years of age (Table 1). Ten of the 38 patients with AMVR (26.3%) 
received a second (n=9) or a third (n=1) transplant (Table 1). Nineteen patients with AMVR 
(50%) presented non-DSA anti-HLA antibodies at transplant. Comparing retransplantations 
to first transplantations within the AMVR group, no difference in the anti-HLA sensitization, 
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neither to class I (5/28 vs. 4/10, P=0.21) nor to class II HLA molecules (6/28 vs. 4/10, P=0.40), 
was observed.  
AMVR was diagnosed at a mean time of 11.2±1.7 days for the 18 patients still requiring 
hemodialysis. For the other 20 patients, AMVR was diagnosed based on an increase in the 
serum creatinine level from 275±187 µmol/L at 15.7±21.4 days to 417±276 µmol/L at 
31.8±7.3 days post-transplantation. 
The AMVR treatment was heterogeneous. However, rituximab was administered to 
31.6% of patients, plasmapheresis to 65.8% and intravenous immunoglobulins to 47.4%, 
suggesting that the patients were considered as having AMR. 
A comparison of patients with DSA- AMVR with matched patients with DSA+ AMR (Table 
1) revealed that patients with DSA- AMVR displayed similar graft function at the rejection 
diagnosis (417±276 µmol/L vs 298±229 µmol/L, P=0.11), more severe graft dysfunction at 3 
months (161±59 µmol/L vs 129±55 µmol/L, P=0.0098), and similar graft function at the last 
follow-up (P=0.23). Consistent with severe graft injury, proteinuria was common in both 
groups, and after a similar follow-up period, the proteinuria in the AMVR cohort was similar 
to the AMR cohort (1.27±1.7 g/g vs 1.0±1.4 g/g, P=0.44). 
The central histological reading of the patients with DSA- AMVR showed severe 
microvascular inflammation, with a mean g+ptc score of 3.9±0.25 (Figure 2A and 2B), and 
severe endothelial/vascular injury (Figure 2C-H). Vasculitis was present in 60.5% of cases, 
and thrombotic microangiopathy and interstitial hemorrhages were observed in 15.8% and 
31.6% of cases, respectively (Table 2).  
Compared to DSA+ AMR biopsies, DSA- AMVR biopsies exhibited more severe 
endothelial/vascular injury, with significantly more v lesions (1.3±1.1 vs 0.3±0.8, P=0.0003), 
a greater number of cases with vasculitis lesions (60.5% vs 15%, P=0.001) and numerically 
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more thrombotic microangiopathy (15.8% vs 0%, P=0.08) (Table 2). Compared to patients 
with AMR, patients in the AMVR group showed significantly more interstitial infiltrates. 
Overall, T cell-mediated rejection defined according to the Banff classification was not 
significantly different between the two groups (31.5% vs 10.0%, P=0.18). 
 
Assessment of known AECAs 
The presence of previously proposed AECAs9, 10 was assessed in available serum samples 
collected at the time of transplant (day 0), corresponding to a mean time of 22.0±26.2 days 
prior to the AMVR diagnosis, in 23 patients with early AMVR and 10 stable KTRs used as 
controls (Supplementary Table 1). 
Anti-MICA Abs were detected in only two patients with AMVR.  
Titers of angiotensin type 1 receptor (AT1R) and endothelin-1 type A (ETAR) Abs were 
similar in both groups (Figure 3A). Regarding AT1R Abs, we did not observe any positivity in 
the AMVR group or in the stable group (Figure 3A) using the threshold of 17 UI/mL proposed 
by Hönger et al.11. When the positive threshold of 10 UI/mL proposed by Dragun et al.2 was 
used, 6/23 patients with AMVR (26%) were positive for AT1R Abs compared to no patients 
(0/10, 0%) in the stable group (P=0.14, chi-square test). However, we observed a good 
correlation between ETAR and AT1R Ab titers, with an r2 greater than 0.8 (P<0.0001), 
suggesting a spread of the Ab response toward more autoreactivity (Figure 3B). 
IgG natural polyreactive antibody (NAb) levels were assessed in serum samples from 
patients with AMVR and control subjects using two separate methods. No difference in IgG 
NAbs was observed between the two groups with either method (Figure 3C). However, as 
reported in Figure 3D, the level of IgG NAbs measured using an ELISA was significantly 
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correlated with the level of anti-ETAR Abs, supporting the view of a broad autoimmune 
component.  
Sera were also tested against a panel of 62 non-HLA antigens (Figure 3E). At the time of 
transplant, 19/23 (83%) patients with AMVR tested positive for at least one of the non-HLA 
antigens examined, whereas no stable patients reached the positivity threshold. Sixteen of 
the 62 antigens were positive in at least one patient with AMVR. A total of 45 antigens were 
found positive, with a maximum of 8 patients with AMVR exhibiting positivity for protein 
kinase C (PKC). Overall, no antigen appeared to be a positive target in the majority of 
patients with AMVR. 
 
EC crossmatch 
Since no AECA candidate explained the majority of AMVR cases, we developed an EC 
crossmatch assay to assess serum reactivity to human microvascular glomerular ECs12. Two 
EC types were used as cellular targets: non-donor-specific primary cultures of human 
vascular arterial ECs and the CiGEnC line, an established thermosensitive conditionally 
immortalized cell line that allows cells to differentiate into glomerular microvascular ECs at 
37°C with a preserved endothelial phenotype. The CiGEnC phenotype observed after 
differentiation is shown in Supplementary Figure 1. As ECs express class I and class II HLA 
antigens, this analysis was restricted to patients with AMVR, stable KTRs or healthy 
volunteers with no circulating anti-HLA Abs to avoid any HLA-dependent cell reactivity. 
Strikingly, the seroreactivity against glomerular ECs was significantly increased in sera from 
patients with AMVR (Figure 4A), whereas limited reactivity was observed in healthy 
volunteers (n=6) or stable KTRs (n=10). Seroreactivity against non-HLA antigens was only due 
to IgG, as no IgM reactivity was observed (data not shown). This IgG reactivity was present 
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on day 0 (Figure 4B) and persisted to the time of rejection. Serial titration of positive sera 
revealed high Ab titers (Figure 4C).  
Crossmatches were also performed in resting ECs and after TNF-α and IFN-γ stimulation 
to better characterize the seroreactivity of patients with AVMR. The stimulated status of the 
CiGEnCs after cytokine treatment was controlled by the upregulation of the HLA molecules 
(Supplementary Figure 2). In healthy controls, even after cell activation, no significant 
reactivity toward glomerular ECs was observed, compared to 89% positivity in patients with 
AMVR. Interestingly, the high-level seroreactivity observed in patients with AMVR did not 
depend on inflammation (Figure 4D), suggesting that the antigen targets are basally 
expressed on CiGEnCs and are not regulated by TNF- or IFN-. Moreover, no significant 
reactivity was observed using primary cultures of human macrovascular ECs as targets, even 
after cell stimulation (Figure 4E), or using human renal epithelial cells as targets. Finally, 
patients with AMVR exhibited higher seroreactivity toward fully differentiated glomerular 
ECs than against undifferentiated ECs (Figure 4F). 
Based on these results, the targeted antigens are selectively and constitutively expressed 
on the surface of glomerular ECs.  
 
Integrated cDNA-protein array analyses of glomerular EC-specific immunogenicity 
As AMVR seroreactivity specifically targeted glomerular ECs but not macrovascular ECs, 
we first assessed the differences in the transcriptomic profiles of these two cell types to 
identify antigens restricted to microvascular ECs (Figure 5A). 
Unsupervised hierarchical clustering of mRNA expression patterns correctly classified the 
microvascular and macrovascular ECs (Figure 5A), suggesting that microvascular glomerular 
ECs have a distinct transcriptomic profile. Next, read count normalizations and group 
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comparisons were performed using three independent and complementary methods that 
identified 3427 differentially expressed transcripts in the two cell types (Supplementary 
Figure 3), including 2195 genes that were significantly overexpressed in microvascular ECs 
compared with macrovascular ECs (available online, www.ebi.ac.uk/fg/annotare E-MTAB-
7003).  
We then used a protein array platform to assess the reactivity of serum samples collected 
immediately before transplantation from 20 patients with early AMVR and 10 patients who 
remained stable over the first year after transplant to approximately 9375 antigens. An 
evaluation of the average signals for the anti-human IgG revealed values that were within 
the expected ranges and were consistent across the arrays, indicating the good quality of the 
samples from both groups. An unsupervised principal component analysis (PCA) revealed a 
clear separation of sera from patients with AMVR from sera from stable patients (Figure 5B) 
suggesting that the global seroreactivity profile of patients with AMVR was different. 
Following normalization, individual antigens from protein arrays were ranked according 
to the frequency of reactivity of AMVR sera compared to control sera. Antigen-specific 
responses must have been more prevalent in the sera from patients with AMVR than in sera 
from the stable patients to be considered an antigen of interest, thus possibly representing 
shared immunogenic events targeting microvascular ECs. Compared with sera from stable 
patients, sera from patients with AMVR preferentially reacted with 136 of 9375 antigens 
(unadjusted P<0.05, Supplementary Table 2), but substantial variability was observed 
among individuals, as illustrated in Figure 5C. 
We next performed an integrated analysis (Figure 1) combining the serological responses 
of the patients with AMVR and stable KTRs to the microvascular EC-specific mRNA 
expression profiles, with the aim of identifying non-HLA Abs in patients with AMVR that 
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target proteins specifically expressed by glomerular microvascular ECs. This strategy allowed 
us to identify a list of 857 matches of immunogenic antigens and overexpressed genes in 
microvascular ECs (Figure 1). 
Because seroreactivity was highly variable among patients with AMVR, we rank-ordered 
the 857 potential targets using a previously described method7 that calculates a global score 
for each candidate by including the frequency of seroreactivity in patients with AMVR 
compared with stable patients and the relative strength of the reactivity. Thus, numerous 
unidentified AECAs are present in patients with AMVR, but not in stable patients (Table 3). 
Finally, 4 genes identified using our integrated RNAseq-protein array analysis were 
selected from Table 3 and validated at the mRNA and protein levels in microvascular ECs. As 
shown in Supplementary Figure 4, the 4 genes, bone morphogenetic protein receptor type 
1A (BMPR1A), ephrin type-B receptor 6 (EPHB6), leiomodin-1 (LMOD1) and myelin basic 
protein (MBP), are expressed in the endothelial crossmatch target cells.  
 
DISCUSSION 
 
The concept that AMR may arise in the absence of anti-HLA DSA is universally accepted13. 
This particular type of rejection is still improperly diagnosed, primarily because of the 
unknown specificity of the non-HLA Abs associated with its manifestation. Its clinical course 
and impact on the transplant outcome are also largely unknown. In an effort to better 
understand this complication, we studied a cohort of highly selected KTRs who experienced 
an AMR that was likely triggered by non-HLA DSAs. 
In addition to circulating Abs, C4d deposition in peritubular capillaries is considered the 
best surrogate of antibody-induced injury, even if this marker is not always detected in 
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patients with conventional AMR14, 15 or in the context of suspected AECA-related AMR3, 16. In 
the absence of a consensus definition, we restricted our inclusion criteria to patients with 
significant microvascular inflammation. In addition, we selected KTRs experiencing acute 
rejection within the first three months after transplantation, resulting presumably from 
preformed Abs. These criteria allowed us to identify patients with a homogeneous clinical 
and pathological presentation. In addition to a severe clinical phenotype, the histological 
assessment revealed a dramatic involvement of the vascular wall with an unusual frequency 
of vasculitis lesions, thrombotic microangiopathy and interstitial hemorrhages. Long-term 
follow-up of these patients revealed allograft dysfunction and glomerular proteinuria that 
were also consistent with an antibody-mediated immune injury. 
Numerous AECAs have been reported in the last decade9. Unlike other targets, AT1R and 
ETAR are well-established effectors in autoimmune diseases affecting the macro- and 
microvasculature. AT1R agonistic antibodies have been associated with preeclampsia, 
malignant/refractory hypertension, and primary aldosteronism17. ETAR agonistic antibodies 
have been associated with systemic sclerosis and systemic lupus erythematosus associated 
with pulmonary hypertension17. Importantly, adoptive transfer experiments18 and 
pharmacological inhibition in animal models19 supported their pathogenic effects. In 
transplantation, the seminal work by Dragun et al. reported not only the association of AT1R 
Abs with refractory vascular rejection, but also their potential pathogenic effects, 
demonstrated by the transfer of AT1R Abs to a rat model of kidney transplantation2. Recent 
studies also suggest the association of AT1R with histological features of ABMR in indication 
renal allograft biopsies20. In the present study, we focused on anti-AT1R2, anti-ETAR21,22 and 
NAbs23,24. While none of these candidates clearly identified our patients with AMVR 
compared to stable KTRs, the more surprising result was that they were all correlated with 
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each other. Indeed, we identified a strong correlation (r2=0.82) between anti-AT1R and anti-
ETAR Abs, a finding that was also reported previously in the context of heart21 and renal 
transplantation10. This observation supports the hypothesis that a broad autoimmune 
response may occur in some patients. Consistent with this hypothesis, Butte et al. previously 
identified an autoantibody signature in patients with renal insufficiency compared to 
controls, thus suggesting that end-stage renal damage may release proteins that are not 
otherwise recognized as self-antigens, leading to an adaptive humoral response25. In 
addition, a longitudinal analysis of the Ab responses of pre-transplantation and post-
transplantation sera using a protein array revealed a significant enrichment of the Ab 
response against kidney compartments, again suggesting that chronic organ damage induces 
a broad autoantibody response7. Interestingly, 26% of our AMVR cases occurred in 
retransplanted patients. Thus, AECAs might develop during a previous transplantation. 
Consistent with this hypothesis, using protein arrays, Li and al. revealed that, in addition to 
HLA sensitization, kidney transplantation is associated with an enrichment of a specific 
antibody response against different kidney compartments suggesting that non-anti-HLA Abs 
might develop in transplant recipients26. Further studies are needed to determine whether 
this autoimmune response observed in patients with end-stage renal disease and transplant 
recipients is due to the release of self-antigens by the damaged organ or to a systemic B cell 
deregulation. In this regard, our observation that the global Ab response before 
transplantation clearly distinguished sera from patients with AMVR from sera from stable 
patients supports the hypothesis of systemic B cell deregulation. More recently, an 
association between endothelial crossmatch positivity and AT1R Abs has also been 
reported27. However, in view of the increased autoimmunity observed in some patients, this 
association does not prove causation. Indeed, the findings reported by Dinavahi et al.28 and 
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Porcheray et al.8 that autoimmune profiles induced by transplantation are unique to each 
individual patient also suggest that this response potentially results from systemic B cell 
deregulation rather than a response to potential cryptic epitopes unmasked during chronic 
renal injury. 
Surprisingly, our assessment of AT1R Abs revealed the paucity of highly positive sera (>17 
UI/mL) for AT1R Abs compared to other published studies of renal transplantation. The small 
sample size and the highly selected cohort are certainly possible explanations for the lack of 
patients with high levels of AT1R Abs. Nevertheless, the cut-off for AT1R Ab positivity 
remains controversial and several studies used a threshold of 10 IU/mL29, while others used 
15 IU/mL5 or even 17 IU/mL11. Using a threshold of 10 IU/mL, Giral et al. reported that 47% 
of patients displayed AT1R Ab positivity before transplant29, while Taniguchi et al. reported 
that 17% of patients displayed AT1R Ab positivity before transplant using a threshold of 15 
IU/mL5. In our study, using a threshold of 10 IU/mL, 6 of 23 the evaluated patients with 
AMVR (26%) would have been considered positive for AT1R Abs, supporting the potential 
role of AT1R Abs in AMVR occurrence. 
We also evaluated the seroreactivity to a panel of 62 non-HLA antigens using two single-
antigen flow bead assays. Although no antigen appeared to be a positive target in the 
majority of patients with AMVR, 8/23 patients with AMVR presented Abs against PKC, 
which has been previously associated with acute rejection and graft loss after kidney 
transplantation30. The assessment of the seroreactivity to the 62 non-HLA antigens (Figure 
3F) facilitated the identification of at least one antigen in 19/23 patients with AMVR, while 
none of the control cases exhibited a positive result, revealing the relatively good 
discriminative capacity of this approach. However, this experiment also confirmed the broad 
and variable reactivity among individuals. Considering the highly variable serum reactivity to 
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non-HLA endothelial antigens, our observation that IgG reactivity toward glomerular 
endothelial cells predicts non-HLA Ab-induced AMRs shares some similarities with historical 
analyses showing an increased rejection risk associated with high Panel Reactive Antibody 
values, prior to the use of sensitive bead assays to more specifically identify anti-HLA DSAs. 
In this respect, if the 62 non-HLA antigen panel used in the present study was 
complemented with new candidate antigens, we may be able to improve our understanding 
of the underlying mechanisms and identify the culprits. 
Although this “candidate gene” approach did not identify irrefutable candidates, our 
crossmatch assay identified preformed IgGs targeting antigens that are constitutively 
expressed on glomerular ECs in a compartment-specific fashion. No response or a minimal 
response to macrovascular cells, epithelial cells and smooth muscle cells was detected (data 
not shown). This reactivity was highly specific to patients with AMVR, thus supporting our 
primary hypothesis that AMVR cases are true AMRs. Notably, an increase in IgG binding was 
not observed between the day of transplantation and the day of rejection (Figure 4B), 
suggesting that non-HLA AECAs are preformed Abs. Figure 4B even shows a small reduction 
in the IgG binding when comparing “day 0” and “at rejection” suggesting that circulating Abs 
may bind to the graft microvessels after transplantation, similar to anti-HLA DSAs31.  
We observed a greater heterogeneity in the results of crossmatches that used 
microvascular ECs compared to macrovascular ECs. The heterogeneous results observed 
with the microvascular CiGEnCs are consistent with our results suggesting that each patient 
has peculiar AECAs and may be due to various titers of the AECAs. The relative homogeneity 
observed when using the macrovascular ECs as targets suggests that the KTRs have no 
antibodies targeting the macrovascular endothelium. Even though our crossmatch analysis 
did not detect IgG binding to macrovascular ECs isolated from unused pieces of artery taken 
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from organ donors before kidney transplantation, we cannot exclude the presence, in kidney 
recipients, of other AECAs targeting antigens that are not strictly specific to the 
microvascular endothelium. However, the specific response to microvascular renal ECs may 
provide some clues regarding the still unexplained observation that auto-Abs targeting ECs 
have no pathogenic consequences in non-transplanted patients32. In addition, their 
specificity toward the microvascular endothelium of the graft organ may explain why their 
pathogenicity is confined to the graft. This confinement to the graft of the pathogenic 
consequences of AECAs may suggest that the pathogenicity of AECAs first requires an 
initiating injury (i.e. ischemia/reperfusion injury, anti-HLA-mediated allo-immune injury, etc 
…). For example, our previous study that assessed the role of natural antibodies suggested 
some additive effect between anti-HLA DSA and natural Abs33, a finding that was also 
observed for anti-HLA DSA and AT1R Abs5, 20, 27, thus suggesting that non anti-HLA 
autoantibodies have the potential to amplify microcirculation injury caused by alloantibodies 
in antibody-mediated transplant rejection32, 34. 
We used non-donor-specific ECs in our crossmatch assays. However, previously identified 
non-anti-HLA AECAs with suspected deleterious effects on the renal allograft, such as AT1R 
or ETAR or natural antibodies, which are considered autoantibodies, have not be confirmed 
to be donor-specific allo-Abs 32. 
Our transcriptomic analysis revealed substantial differences in transcriptomic profiles 
between macrovascular and microvascular ECs, suggesting that the endothelial crossmatch 
performance will be highly dependent on the endothelial cell that is used as the target. The 
cell-based assays that have been developed to date have used various endothelial cells 
(HUVECs35, primary cultures of macrovascular arterial endothelial cells36, and circulating 
endothelial progenitors37) but have never used the endothelial cells that are actually the 
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target cells during the pathological process (i.e., the renal microvascular ECs). To the best of 
our knowledge, our EC crossmatch assay is the first to use the target cells of the pathogenic 
Abs in KTRs. Of course, renal microvascular endothelial cells cannot realistically be derived 
from every donor. Therefore, the availability of the CiGEnCs may facilitate the development 
of cell-based assays with a good capability of detecting non-anti-HLA AECAs.  
In an effort to identify the culprits, we profiled the global IgG Ab responses in patients 
AMVR and compared them to controls using protein arrays. The two main conclusions of this 
“antibodyome-wide” approach were that the global antibodyome correctly classified 
patients with AMVR, but no single specific Ab explained the disease, although several Abs 
that emerged from our combined analysis of transcriptomic and proteomic data have been 
already reported in the context of autoimmune diseases (Supplementary Discussion). The 
protein array we used in the present study was not customized to contain endothelia-
specific antigens and/or the whole spectrum of glomerular antigenic molecules, which may 
have led to false negative or false positive results. Nevertheless, our combined 
transcriptomic and proteomic approach identified new potential targets, and the expression 
of several of these targets in the glomerular endothelial cells was validated (Supplementary 
Figure 4), thus confirming the rationale of our approach. Finally, patients suffering from non-
HLA Ab-induced AMRs exhibit profound alterations of their seroreactivity, but with little 
redundancy, and some of their Abs are able to bind to glomerular cells. Altogether, our 
observations complement the aforementioned literature and suggest that an attempt to 
identify a common Ab that may explain the entire spectrum of disease may not succeed. 
If a cell-based assay designed to detect AECAs in patient serum is an appealing strategy to 
circumvent the large individual variability in AECA specificities, it remains a challenging 
technique for several reasons, such as the variability in cell quality and surface antigen 
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expression, the need for cell culture expertise, and the inability to test high PRA sera. The 
risk of cell variability is limited by the use of a well-phenotyped cell line as opposed to 
primary cultures of ECs or purified circulating endothelial progenitors. Our robust 
endothelial phenotyping approach facilitates a longitudinal assessment of the stability of the 
cell line over time. Finally, AECA detection must be feasible even in highly sensitized 
patients. As a human cell line, CiGEnCs express class I and class II HLA molecules that may 
lead to a positive endothelial cell crossmatch due to the presence of anti-HLA antibodies in 
sensitized recipients. The CRISPR/Cas9 technology will be used to delete HLA molecules from 
the CiGEnC line and establish an endothelial crossmatch that could be useful as a screening 
test for AECA assessment, even in highly sensitized patients. Finally, the observed binding of 
AECAs to the CiGEnCs may enable the more precise identification of the antigenic targets, 
thus facilitating the refinement of the existing solid phase assays for AECA identification. 
Expectedly, the development of a cell-based assay using a single cell line would not account 
for the potential donor genetic heterogeneity and would be more suitable for assessment of 
auto-antibodies that recognize public antigens following a disruption of self-tolerance, as 
opposed to allo-antibodies targeting non-HLA polymorphic antigens. A test that could 
address the tremendous inter-individual variability in terms of auto-antibody response could 
constitute a relevant companion test that could screen for the presence of circulating AECA 
in conjunction with the ‘candidate gene’ approach. 
In conclusion, we addressed the challenging problem of AMR in the absence of anti-HLA 
Abs in an original way by identifying a highly selected cohort of patients who likely suffered 
from this unusual and difficult-to-diagnose entity. Previously identified non-HLA Abs failed to 
differentiate patients with AMVR from stable patients, but an innovative EC crossmatch 
identified a universal IgG reactivity to microvascular glomerular ECs. An in-depth integrated 
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analysis of transcriptomic and proteomic data revealed a large Ab response mediated by 
deregulation with little redundancy among individuals. Based on our results, in vitro cell-
based assays are needed to assess the presence of EC Abs with a potential deleterious effect 
after transplantation.  
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Table 1: Patient demographics 
Variables 
AMVR without 
anti-HLA DSAs, 
N=38 
AMVR with anti-
HLA DSAs, N=20 
P 
Recipient characteristics    
     Male, n (%) 25 (65.8) 13 (65.0) 1.00 
     Age at transplantation, mean±SD, yrs 43.0±14.3 50.4±15.9 0.11 
     Cause of end-stage renal disease, n (%) 
          Glomerulonephritis 
          Diabetes 
          Cystic/hereditary/congenital 
          Secondary glomerulonephritis 
          Hypertension 
          Interstitial nephritis 
          Miscellaneous conditions 
          Uncertain etiology 
 
10 (26.3) 
6 (15.8) 
7 (18.4) 
3 (7.9) 
2 (5.3) 
3 (7.9) 
2 (5.4) 
5 (13.2) 
 
4 (20.0) 
5 (25.0) 
3 (15.0) 
2 (10.0) 
0 (0.0) 
2 (10.0) 
3 (15.0) 
1 (5.0) 
 
0.75 
0.49 
1.00 
1.00 
0.54 
1.00 
0.33 
0.65 
     Duration of dialysis before transplantation, mean±SD, yrs 3.9±4.4 4.8±4.9 0.44 
     Previous transplantation, n (%) 10 (26.3) 3 (15.0) 0.51 
Transplant variables    
      Donor age, mean±SD, yrs 50.4±12.6 52.3±17.4 0.93 
      Deceased donor, n (%) 28 (73.7) 17 (85.0) 0.51 
      Male donor, n (%) 17 (44.7) 8 (40.0) 0.79 
      Cold ischemia time, mean±SD, hrs 15.9±10.4 20.5±9.7 0.13 
      Preformed anti-HLA Abs with an MFI>500, n (%) 19 (50.0) 20 (100.0) <0.0001 
      Delayed graft function, n (%) 18 (47.3) 7 (35.0) 0.41 
      Number of post-transplant hemodialysis session, mean±SD 2.5±4.2 2.4±2.9 0.39 
Immunosuppressive protocol    
      Induction therapy, n (%) 38 (100.0) 19 (95.0) 0.34 
           Basiliximab/Thymoglobuline®, n (%) 33 (86.8)/5 (13.2) 14 (75.0)/5 (25.0) 0.28 
      Calcineurin inhibitor-based therapy, n (%) 37 (97.4) 20 (100.0) 1.0 
           Cyclosporine/Tacrolimus, n (%) 11 (28.9)/26 (68.4) 3 (15.0)/17 (85.0) 0.34 
      Purine synthesis inhibitor, n (%) 37 (93.9) 19 (95.0) 0.35 
      mTOR inhibitor, n (%) 0 (0.0) 1 (5.0) 0.35 
      Steroid, n (%) 37 (97.4) 20 (100.0) 1.0 
Acute rejection description    
    Best serum creatinine level before AMVR, mean±SD, µmol/L 275±187 195±137 0.15 
    Best serum creatinine level before AMVR, mean±SD, days 15.7±21.4 8.5±8.2 0.64 
    AMVR diagnosis, mean±SD, days 22.0±26.2 15.9±13.5 0.92 
    Serum creatinine level at rejection, mean±SD, µmol/L 417±276 298±229 0.11 
    Patients on dialysis at time of rejection 8 (21.1) 1 (0.05) 0.14 
Acute rejection treatment    
     Steroid, n (%) 35 (92.1) 19 (95.0) 1.00 
     Thymoglobuline®, n (%) 10 (26.0) 2 (10.0) 0.19 
      Rituximab, n (%) 12 (31.6) 10 (50.0) 0.25 
      Plasmapheresis, n (%) 25 (65.8) 15 (75.0) 0.56 
      IGIV, n (%) 18 (47.4) 17 (85.0) 0.01 
Follow-up    
      Serum creatinine level at 3 months post-Tx, mean±SD, µmol/L 161±59 129±55 0.0098 
      Serum creatinine level at 12 months post-Tx, mean±SD, 
µmol/L 
145±53 
125±41 0.08 
      Mean follow-up, mean±SD, yrs 4.3±3.0 3.5±2.7 0.25 
      Serum creatinine level at the last follow-up, mean±SD, µmol/L 169±97 136±76 0.23 
      Proteinuriaa at the last follow-up, mean±SD, g/g creatinine  1.27±1.7 (n=20) 1.0±1.4 (n=18) 0.44 
      Patient survival at the last follow-up, n (%) 37 (97.3) 18 (90.0) 0.12 
      Graft survival at the last follow-up, n (%) 29 (76.3) 19 (95.0) 0.51 
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a in patients with a follow-up >1 yr   
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Table 2: Description of the histological findings 
Histological lesions 
AMVR without        
anti-HLA DSAs, N=38 
AMVR with anti-
HLA DSAs, N=20 
P 
Glomerulitis (g) 
     % with a g score>0 
     g score, mean±SD 
 
38 (100.0%) 
2.1±0.8 
 
18 (90.0%) 
1.7±0.9 
 
0.11 
0.18 
Peritubular capillaritis (ptc) 
     % with a ptc score>0 
     ptc score, mean±SD 
 
36 (94.7%) 
2.0±0.9 
 
19 (95.0) 
1.7±0.7 
 
1.0 
0.66 
C4d deposition (C4d) 
     % with a C4d score>0 
     C4d score, mean±SD 
 
9 (23.7%) 
0.5±1.1 
 
3 (15.0%) 
0.5±0.8 
 
0.52 
0.98 
Interstitial infiltrates (i) 
     % with an i score>0 
     i score, mean±SD 
 
21 (55.3%) 
0.9±1.0 
 
2 (10.0%) 
0.1±0.3 
 
0.0008 
0.003 
Tubulitis (t) 
     % with a t score>0 
     t score, mean±SD 
 
14 (36.8%) 
1.1±1.1 
 
14 (70.0%) 
0.5±0.7 
 
0.03 
0.02 
TCMR diagnostic criteria, n (%) 
     IA, n (%) 
     IB, n (%) 
     IIA, n (%) 
     IIB, n (%) 
     III, n (%) 
8 (21.1%) 
3 (8.8%) 
3 (8.8%) 
0 (0%) 
1 (2.6%) 
1 (2.6%) 
2 (10.0%) 
2 (10.0%) 
0 (0%) 
0 (0%) 
0 (0%) 
0 (0%) 
0.18 
0.29 
0.27 
1.00 
1.00 
1.00 
Vasculitis (v) 
     % with a v score>0 
     v score, mean±SD 
 
23 (60.5%) 
1.3±1.1 
 
3 (15.0%) 
0.3±0.8 
 
0.0003 
0.0003 
Interstitial hemorrhages, n (%) 12 (31.6) 3 (15.0) 0.22 
Thrombotic microangiopathy, n (%) 6 (15.8) 0 (0.0) 0.08 
Allograft glomerulopathy (cg) 
     % with a cg score>0 
     cg score, mean±SD 
 
0 (0.0%) 
0.0±0.0 
 
0 (0.0%) 
0.0±0.0 
 
1.00 
1.00 
Mesangial expansion (mm) 
     % with an mm score>0 
     mm score, mean±SD 
 
2 (5.3%) 
0.1±0.4 
 
0 (0.0%) 
0.0±0.0 
 
0.54 
0.59 
Interstitial fibrosis (ci) 
     % with a ci score>0 
     ci score, mean±SD 
 
4 (10.5%) 
0.2±0.7 
 
4 (20.0%) 
0.3±0.6 
 
0.43 
0.97 
Tubular atrophy (ct) 
     % with a ct score>0 
     ct score, mean±SD 
 
4 (10.5%) 
0.2±0.7 
 
4 (20.0%) 
0.2±0.4 
 
0.42 
0.80 
Chronic vascular changes (cv) 
     % with a cv score>0 
     cv score, mean±SD 
 
16 (42.1%) 
1.0±1.1 
 
13 (65.0%) 
0.9±1.1 
 
0.16 
0.87 
Arteriolar hyalinosis (ah) 
     % with an ah score>0 
     ah score, mean±SD 
 
15 (39.5%) 
0.8±0.9 
 
11 (55.5%) 
0.8±1.1 
 
0.28 
0.59 
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Table 3: Top 20 immunogenic antigens in patients with AMVR of 857 candidate antigens overexpressed in microvascular ECs 
Gene ENS Symbol 
Delta 
Expression in 
Micro ECs vs 
Macro ECs 
Protein Locus Description 
Frequency 
in Stable 
Patients 
Freque
ncy in 
Patient
s with 
AMVR 
Intensity 
in Stable 
Patients 
Intensity 
in 
Patients 
with 
AMVR 
Overall 
Score 
P Value 
ENSG00000162078 ZG16B 148.5 NM_145252.1 
zymogen granule 
protein 16B 
33.33% 90.91% 2.11 2.92 87.2 0.0004 
ENSG00000163431 LMOD1 144.8 BC001755.1 leiomodin 1 25.00% 68.18% 1.04 1.99 60.4 0.0131 
ENSG00000107779 BMPR1A 1782.7 NM_004329 
bone morphogenetic 
protein receptor, type IA 
16.67% 72.73% 0.87 1.03 57.4 0.0011 
ENSG00000197971 MBP 4251.9 NM_001025100.1 myelin basic protein 25.00% 63.64% 1.11 2.16 56.4 0.0251 
ENSG00000169188 APEX2 23.7 NM_014481.2 APEX nuclease 2 25.00% 77.27% 0.93 1.09 55.0 0.0027 
ENSG00000106789 CORO2A 433 NM_052820.1 
coronin, actin binding 
protein, 2A 
33.33% 63.64% 1.01 2.34 51.1 0.1810 
ENSG00000183287 CCBE1 15174.7 BC046645.1 
collagen and calcium 
binding EGF domains 1 
8.33% 45.46% 0.60 1.59 46.0 0.0621 
ENSG00000145242 EPHA5 1609.2 PV3359 EPH receptor A5 25.00% 63.64% 0.90 1.23 44.0 0.0771 
ENSG00000106829 TLE4 1281.9 BC059405.1 
transducin-like 
enhancer of split 4 
33.33% 68.18% 2.05 1.99 43.5 0.0451 
ENSG00000142459 EVI5L 1270.2 NM_145245.1 
ecotropic viral 
integration site 5-like 
25.00% 59.09% 0.84 1.33 41.4 0.1225 
ENSG00000107679 PLEKHA1 2978.9 NM_001001974.1 
pleckstrin homology 
domain containing, 
family A1 
16.67% 45.46% 0.69 1.71 39.7 0.0621 
ENSG00000198959 TGM2 28594.6 BC003551.1 transglutaminase 2 8.33% 45.46% 0.68 0.96 37.6 0.0621 
ENSG00000082805 ERC1 2673.4 PV3626 
ELKS/RAB6-
interacting/CAST family 
member 1 
8.33% 31.82% 0.39 2.31 36.0 0.0653 
ENSG00000198081 ZBTB14 285.7 NM_003409.2 
zinc finger and BTB 
domain containing 14 
33.33% 63.64% 0.94 1.25 36.0 0.1810 
ENSG00000128872 TMOD2 560.4 BC036184.1 tropomodulin 2 16.67% 50.00% 0.85 1.09 35.6 0.0369 
ENSG00000168175 MAPK1IP1L 3083.3 NM_144578.1 
mitogen-activated 
protein kinase 1 
interacting protein 1-like 
8.33% 40.91% 0.60 1.12 35.5 0.0215 
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ENSG00000112561 TFEB 171.1 NM_007162.1 transcription factor EB 8.33% 40.91% 0.62 0.99 33.7 0.0215 
ENSG00000123836 PFKFB2 596.2 NM_006212.1 
6-phosphofructo-2-
kinase/fructose-2,6-
biphosphatase 2 
41.67% 68.18% 1.09 1.40 33.4 0.1183 
ENSG00000106123 EPHB6 119.4 NM_004445.1 EPH receptor B6 8.33% 36.36% 0.69 1.14 30.6 0.1540 
ENSG00000240694 PNMA2 684.4 XM_376764.2 
paraneoplastic Ma 
antigen 2 
8.33% 36.36% 0.65 1.10 30.3 0.0381 
 
*Intensity represents the average ratio of observed reactivity exceeding the cut-off for sera from stable patients and patients with AMVR. 
† The score was calculated using the equation  (FreqAMVR  × √IntensityAMVR
   3 ) - (FreqStable  × √IntensityStable
   3 ) described by Gnjatic et al7.   
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FIGURE LEGENDS  
 
Figure 1: Study design and workflow. A nationwide survey identified patients suspected 
having of early (<3 months post-transplant) microvascular (g+ptc score≥3 according to the 
Banff classification) rejections of a renal allograft. After centralized Luminex® SAFB assay 
testing and central reading of the biopsies, 38 patients were retained for two parallel 
substudies. A case-control histological study (Study #1) addressed the histological 
characteristics of the 38 acute microvascular rejections compared to 20 patients with early 
acute antibody-mediated rejection associated with anti-HLA donor-specific antibodies. A 
case-control biological study (Study #2) focused on identifying non-HLA antibodies using 
several approaches and used pretransplant serum samples from unsensitized KTRs who 
remained stable during the first year after transplant and were used as controls. Finally, an 
integrated analysis of transcriptomic and proteomic data was performed to identify 
antibodies targeting glomerular cell-specific antigens (Study #3). For this aim, the differential 
transcriptomic profiles of microvascular glomerular ECs and macrovascular ECs were 
combined with the global seroreactivity toward protein arrays of serum samples collected 
immediately before transplantation from KTRs with AMVR or stable KTRs. 
 
Figure 2: Representative pathological characteristics of the early AMVRs. (A.) Mean (SEM) 
values of the elementary lesions assessed using the Banff classification in the biopsy samples 
from 38 KTRs at time of acute microvascular rejection. (B.) The g+ptc scores of the 38 
individual patients with AMVR. (C.) Image of Periodic acid–Schiff (PAS) staining showing 
severe glomerulitis with partial to complete occlusion of glomerular capillaries by infiltrating 
leukocytes (mononuclear cells and neutrophils cells) (arrow). (D.) Image of PAS staining 
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showing severe peritubular capillaritis (ptc3) with more than 10 inflammatory cells in dilated 
capillaries (arrow) associated with diffuse interstitial edema (✚). (E.) Image of PAS staining 
showing intimal arteritis v2 with mononuclear cells underneath the endothelium and 
occlusion of more than 25% of the arterial lumen (★) associated with peritubular capillaritis 
(✚) and sparse inflammatory cells within the interstitium. (F.) Image of Masson-s trichrome 
staining showing severe glomerulitis with complete occlusion of glomerular capillaries by 
infiltrating leukocytes and EC enlargement. EC enlargement is also present in arterioles 
(arrow). (G.) Image of Masson’s trichrome staining showing thrombotic microangiopathy 
characterized by thrombi in the glomerular capillaries (★) associated with glomerulitis, 
peritubular capillaritis and diffuse interstitial hemorrhage (✚). (H.) Image of Masson's 
trichrome staining showing a mixed rejection with diffuse interstitial inflammation and 
tubulitis (arrow), glomerulitis ✪, peritubular capillaritis (✚), arteriolitis (★) and interstitial 
hemorrhage. 
 
Figure 3: Assessment of known AECAs. (A.) Titers of anti-AT-1R and anti-ETAR antibodies in 
serum samples collected on the day of transplantation from 23 patients with early AMVR 
without anti-HLA donor-specific antibodies and 10 nonsensitized KTRs who did not 
experience any rejection during their first year after transplant and were used as controls. P 
values were determined using the Mann-Whitney test. (B.) Assessments of natural 
polyreactive antibodies were conducted using flow cytometry to detect reactivity to 
apoptotic cells or using a dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA) to 
detect reactivity to malondialdehyde (MDA) in 19 patients with AMVR and 8 controls. P 
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values were determined using the Mann Whitney test. (C.) Correlation between anti-AT-1R 
and anti-ETAR antibody titers at the time of transplantation. (D.) Correlation between NAbs 
reactive to MDA and anti-ETAR antibodies at the time of transplantation. (E.) Correlation 
between NAbs reactive to MDA and anti-AT-1R antibodies at the time of transplantation. (F.) 
Analysis of the seroreactivity of serum samples from 10 stable patients and 23 patients with 
AMVR toward 62 non-HLA antigens using single-antigen flow bead assays. The color of each 
box indicates the MFI of the reaction of the sample to an individual antigen. The thresholds 
for defining a positive reaction of the patients with to each individual antigen were 
calculated based on the mean MFI of the control group of stable patients. Samples with an 
MFI less than the mean+3 standard deviations (SD) were classified as negative and samples 
with an MFI greater than the mean+3 SD were classified as positive. The number of positive 
samples is provided on the right and the samples that reached the threshold for positivity 
are indicated with a cross.   
 
Figure 4: EC crossmatch assays. Sera (diluted 1:4) were incubated with ECs. Antibody 
binding was detected using fluorescently labeled anti-human IgG, and the MFI was 
measured using flow cytometry. (A.) Comparison of the reactivity of sera from healthy 
volunteers (HV, n=6) and KTRs with (n=19) or without (n=10) early AMVR and without anti-
HLA DSAs toward unstimulated immortalized human glomerular CiGEnCs. The data are 
presented as a fold increase in the MFI compared to a pool of AB serum samples used as 
negative control. The P value was calculated using the Kruskal–Wallis test. Asterisks depict 
significant differences in pairwise group comparisons calculated using Dunn’s post test. 
***P<0.01 and ****P<0.001. (B.) Sera (diluted 1:4) collected on the day of transplantation 
or at rejection from 4 patients with AMVR without anti-HLA DSAs were incubated with 
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unstimulated microvascular CiGEnCsECs. Representative histograms showing IgG binding are 
shown; values indicate the geometric MFIs. (C.) Serial dilutions of sera from patient 
AMVR#11 or a pool of healthy volunteers were incubated with renal microvascular CiGEnCs 
before the detection of antibody binding using anti-human IgG. Data are presented as the 
geometric MFIs. (D and E.) Sera (diluted 1:4) collected on the day of transplantation from 19 
patients with AMVR were incubated with renal microvascular CiGEnCs (D.) or primary 
cultures of macrovascular arterial ECs (E.) before (unstimulated) or after a 48-h stimulation 
with TNF and IFNγ. A pool of AB sera was used as a negative control (CTL). A cut-off of a 2-
fold increase in the geometric mean value of patients’ sera compared with the negative 
control was established to define reactive sera.  (F.) Sera (diluted 1:4) collected on the day of 
transplantation from 2 patients with early AMVR or a pool of serum samples from healthy 
volunteers (HV, n=6) were incubated with renal microvascular ECs or epithelial cells. 
Microvascular ECs were used before or after in vitro differentiation. Representative 
histograms showing IgG binding are shown, and the values indicate the geometric MFIs. 
 
Figure 5: Integrated RNAseq-protein array analysis 
(A.) Unsupervised PCA of the global seroreactivity profiles of serum samples collected 
immediately before transplantation from patients with AMVR (n=20) and stable KTRs (n=10). 
Average fixation signals of the immunogenic antigens were used. Ellipses of confidence 
(0.95) are presented for each group. (B.) Clustering and heat map representations of the 
transcriptomic data from microvascular and macrovascular ECs. Cell samples (n=3 for 
microvascular ECs and n=5 for macrovascular ECs) are arranged along the x-axis, whereas 
differentially expressed genes (n=3427) are arranged along the y-axis. The color of each cell 
reflects the fold change in the expression of each gene. (C.) Heat map representation of the 
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seroreactivity patterns of patients with AMVR and stable KTRs. Sera are arranged along the 
x-axis, whereas immunogenic antigens are arranged along the y-axis. The color of each cell 
reflects the normalized average fixation signal of an individual serum to one antigen.  
 
 
